相关实验视频
Updated: Feb 22, 2026
09:11
Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
7.0K
通过非酸盐[1,2,4]三[4,3-a]类化合物进行向的HDAC8抑制
N V M Rao Bandaru1,2, Ashna Fathima3, Suryansh Sengar3
1Department of Chemistry, Birla Institute of Technology and Science, Pilani, Hyderabad Campus, Jawahar Nagar, Hyderabad, Telangana, 500 078, India.
Scientific reports
|February 20, 2026
概括
新的[1,2,4]三醇[4,3-a]类衍生物显示出作为基因素脱乙酶8 (HDAC8) 抑制剂的前景. 这些化合物通过抑制生长和扩散有效地向神经母细胞瘤细胞,提供了潜在的新治疗策略.
科学领域:
- 药用化学 医学化学
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 基因脱乙酶8 (HDAC8) 在基因表达和瘤发育中起着至关重要的作用,特别是在神经母细胞瘤中.
- 准HDAC8是开发新型癌症疗法的有希望的策略.
研究的目的:
- 设计,合成和评估新的替代[1,2,4]Triazolo[4,3-a]类衍生物作为潜在的HDAC8抑制剂.
- 研究这些化合物对神经母细胞瘤的分子相互作用和生物疗效.
主要方法:
- 新型[1,2,4]三醇[4,3-a]类衍生物的合成.
- 分子对接和分子动力学模拟以评估与HDAC8.8的结合相互作用.
- 使用神经母细胞瘤细胞系 (IMR-32) 和其他癌症/正常细胞系 (HCT116,MCF7,HEK293) 的体外分析.
- 细胞周期,细胞亡,殖民地形成,细胞迁移和SMC3乙化试验.
主要成果:
- 新型化合物显示出强大而稳定的抑制HDAC8.
- 化合物9h和9m显著有效,特别是在神经母细胞瘤细胞中,对其他细胞系的影响很小.
- 观察到抑制神经母细胞瘤细胞生长,迁移和诱导亡.
- 增加的SMC3乙化证实了抑制剂的目标参与.
结论:
- 设计的[1,2,4]Triazolo[4,3-a]类衍生物是有效的非酸盐HDAC8抑制剂.
- 这些化合物显示出强大的潜力,作为神经母细胞瘤治疗的治疗剂.
- 这些抑制剂的进一步开发是必要的,以获得临床应用.
相关概念视频
02:34Inhibition of Cdk Activity
6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
2.8K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.8K
01:23Dipeptidyl Peptidase 4 Inhibitors
759
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
759